Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH

Treatment of Nonalcoholic fatty liver disease (NAFLD) constitutes an unmet clinical need owing to the relatively limited efficacy of both novel and readily available metabolic medications, thus warranting pathobiological investigations on the mechanisms of single or combination regimens. In this con...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Endocr Soc
Main Authors: Perakakis, Nikolaos, Stefanakis, Konstantinos, Feigh, Michael, Veidal, Sanne S, Mantzoros, Christos S
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2021
Teme:
Cardiovascular Endocrinology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089912/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.642
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki